Investor Call Reveals MRD Test Volumes Surging 38% QoQ, Only 10% of Sales Force Deployed, and 2027 Profitability Target Intact After Personalis Acquisition

summarizeSummary

Tempus AI's investor call on the Personalis acquisition revealed MRD test volumes growing 38% QoQ to ~9,000 in Q2 2026, with only 10% of the sales force deployed, and reaffirmed a 2027 profitability target. The deal adds a best-in-class tumor-informed MRD assay to Tempus's portfolio, with significant commercial and data synergies ahead.

check_boxKey Events · M&A and Partnerships · TEM

• MRD Test Volumes Surge 38% QoQ

  NeXT Personal test volumes distributed by Tempus reached ~9,000 in Q2 2026, up from ~6,500 in Q1 2026, a 38% quarter-over-quarter increase. This growth occurred with only 10% of Tempus's sales force actively selling MRD solutions.

• Acquisition Price and Structure

  Tempus will acquire all outstanding Personalis shares not already owned for $16.25 per share, a 6% premium to the prior close and 28% premium to the 30-day VWAP. Consideration is 100% stock with a floating exchange ratio capped at 0.3356 TEM shares per PSNL share; Tempus has the option to pay up to 50% in cash.

• 2027 Profitability Target Reaffirmed

  Management stated that even with the acquisition, Tempus intends to be EBITDA and free cash flow positive in 2027, absorbing Personalis's near-term losses through growing gross profit dollars from the core therapy selection and data businesses.

• Strategic Data and Commercial Synergies

  Post-close, Tempus will integrate Personalis's longitudinal MRD data into its multimodal data flywheel, enhancing biopharma insights for biomarker discovery, patient selection, and trial optimization. The combined portfolio offers a complete suite from hereditary risk to therapy selection to recurrence monitoring.

auto_awesomeAnalysis · TEM · Industrial Applications And Services

This investor call transcript adds critical new details to the $1.5 billion Personalis acquisition announced earlier today. Tempus disclosed that its distributed NeXT Personal MRD test volumes jumped 38% quarter-over-quarter to ~9,000 tests in Q2 2026, yet only 10% of its sales force is currently selling MRD — signaling massive untapped growth potential as reimbursement expands. Management confirmed the combined company remains on track for EBITDA and free cash flow positivity in 2027, absorbing Personalis's near-term losses through core business gross profit growth. The floating exchange ratio (max 0.3356 TEM shares per PSNL share) and Tempus's option to pay up to 50% cash provide deal structure clarity. The call also underscored the strategic data flywheel benefits: integrating Personalis's longitudinal MRD data with Tempus's AI models to enhance biopharma offerings. These specifics transform the acquisition from a headline into a quantifiable growth and synergy story.